Cyclosporine

證據等級: L5

預測適應症: 7 個

Cyclosporine: From Organ Transplant Rejection to Chronic Granulomatous Disease

One-Sentence Summary

Cyclosporine is a calcineurin inhibitor widely established as immunosuppressive therapy to prevent organ transplant rejection and graft-versus-host disease (GvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). The TxGNN model predicts it may be effective for Granulomatous Disease, Chronic, Autosomal Recessive (CGD), with 1 clinical trial and 1 publication currently supporting this direction — primarily in the context of HSCT regimens that represent the only curative strategy for CGD, where Cyclosporine serves as standard GvHD prophylaxis.

Quick Overview

Item	Content
Original Indication	No regulatory data available in current dataset (established use: organ transplant rejection, GvHD prophylaxis)
Predicted New Indication	Granulomatous Disease, Chronic, Autosomal Recessive (CGD)
TxGNN Prediction Score	99.68%
Evidence Level	L3
US Market Status	Not found in current dataset (likely data collection gap)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on information embedded in the mechanistic rationale, Cyclosporine is a calcineurin inhibitor that blocks the NFAT (Nuclear Factor of Activated T-cells) signaling pathway, thereby suppressing T cell activation and IL-2 secretion. It is a standard component of immunosuppressive regimens following organ transplantation and allo-HSCT, where it serves to prevent GvHD.

Chronic Granulomatous Disease (CGD) is a rare primary immunodeficiency caused by mutations in components of the NADPH oxidase complex (most commonly the CYBB gene encoding gp91phox). The functional consequence is the inability of phagocytes to generate reactive oxygen species, rendering patients susceptible to life-threatening infections with catalase-positive bacteria and fungi. The only curative treatment is allo-HSCT — and herein lies the connection to Cyclosporine.

The mechanistic link is indirect: Cyclosporine does not correct the underlying NADPH oxidase defect in CGD, nor does it enhance phagocyte killing function. Rather, it enables successful HSCT by suppressing donor T cells and preventing GvHD, thereby allowing engraftment of healthy donor hematopoietic stem cells that reconstitute a functional immune system. The TxGNN prediction almost certainly reflects the strong co-occurrence of Cyclosporine and CGD within HSCT-related nodes in the knowledge graph, rather than a novel, direct therapeutic mechanism for the disease itself. This distinction is critical to interpreting the prediction’s clinical relevance.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01917708	Phase 1	Completed	10	Evaluated abatacept (CTLA4-Ig) combined with Cyclosporine + mycophenolate mofetil as GvHD prophylaxis in children undergoing unrelated donor HSCT for serious non-malignant diseases (including CGD). Cyclosporine functions as background GvHD prophylaxis; the investigational agent is abatacept. The trial confirms CGD is treated via HSCT but does not directly assess Cyclosporine’s independent efficacy in CGD.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22078471	2012	Cohort	J Allergy Clin Immunol	Retrospective cohort demonstrating excellent survival after matched related or unrelated donor HSCT for CGD. Validates allo-HSCT (employing standard Cyclosporine-containing conditioning regimens) as a curative strategy for CGD in both pediatric and adult patients. Cyclosporine is part of the GvHD prophylaxis protocol, not the subject of independent evaluation.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic connection between Cyclosporine and CGD is indirect — Cyclosporine functions as GvHD prophylaxis within the HSCT procedure that cures CGD, rather than as a direct therapeutic agent targeting the NADPH oxidase deficiency. With L3 evidence comprising a single cohort study confirming HSCT efficacy and one Phase 1 trial where Cyclosporine is a background medication rather than the investigational drug, there is insufficient evidence to advance this as a novel repurposing candidate distinct from Cyclosporine’s already-established role in transplant medicine.

To proceed, the following is needed:

Research question clarification: Define whether the goal is (a) optimizing Cyclosporine-based GvHD prophylaxis protocols specifically within CGD HSCT, or (b) exploring any direct immunomodulatory role of Cyclosporine in CGD pathophysiology independent of HSCT
Mechanism of action data: Retrieve full MOA entry from DrugBank (DB00091) to formally document calcineurin inhibition pathway
Regulatory data correction: Verify US FDA approval status — current dataset shows 0 licenses, which is inconsistent with Cyclosporine’s well-established global clinical use (multiple approved formulations known to exist); re-query pipeline required
Safety data: Retrieve package insert warnings and contraindications from source to complete safety assessment before any S1 evaluation can proceed
Dedicated clinical evidence: A trial prospectively evaluating Cyclosporine-specific dosing, timing, and outcomes in CGD HSCT would be needed to distinguish Cyclosporine’s contribution from the overall transplant procedure effect
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.